Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Stoke Therapeutics's pretax income for the
three
months ended in Jun. 2026 was $-61.62 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-209.18 Mil.
Stoke Therapeutics's pretax margin was -660.78%.
During the past 9 years, Stoke Therapeutics's highest Pretax Margin was -3.73%. The lowest was -1192.47%. And the median was -529.08%.
During the past 9 years, Stoke Therapeutics's highest Pretax Margin was -3.73%. The lowest was -1192.47%. And the median was -529.08%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics Pre-Tax Income Related Terms
Stoke Therapeutics Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Stoke Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STOK vs ZBIO, ZYME, COAG: Pre-Tax Income Comparison
For the Biotechnology subindustry, Stoke Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-209.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics (STOK) has a Pre-Tax Income of $-209.18 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Stoke Therapeutics and its competitors.
Is Stoke Therapeutics' Pre-Tax Income too high?
Stoke Therapeutics' current Pre-Tax Income is $-209.18 Mil. Overall, Stoke Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Pre-Tax Income compare to ZBIO and ZYME?
Stoke Therapeutics' Pre-Tax Income of $-209.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Stoke Therapeutics and its competitors. Stoke Therapeutics's current Pre-Tax Income is $-209.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.85, compared to a current price of $29.03 — trading 194.7% above its estimated fair value. The current Pre-Tax Income is $-209.18 Mil. Stoke Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current Pre-Tax Income is $-209.18 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (STOK) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of $29.03 is trading 194.7% above its estimated GF Value™ of $9.85.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for STOK:
Pre-Tax Income: $-209.18 Mil
GF Value™: $9.85 vs. price of $29.03 (194.7% above fair value)
No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
44GF Score
Get the complete analysis for STOK
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STOK has been successfully added to your 
